Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
OXFORD, England, November 30, 2007 /PRNewswire/ -- Chroma Therapeutics Limited announced today that it will report efficacy data from a Phase I clinical trial of its oral, once-daily experimental cancer therapy CHR-2797 at the forthcoming American Society of Hematology (ASH) meeting. CHR-2797 is the only oral aminopeptidase inhibitor currently in clinical development. The company will also be presenting the results of various preclinical studies. Details of the presentations are as follows:
Abstract # 443: oral presentation
Title: A Phase I Study of CHR-2797, an Orally Active Aminopeptidase
Inhibitor in Elderly and/or Treatment Refractory Patients with Acute
Myeloid Leukemia
Location and timing: Acute Myeloid Leukemias: Therapy, excluding
Transplantation-Novel Therapies, Rooms A411-A412: Monday December 10,
2007, 13:30-15:00 Eastern Standard Time
Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)
Abstract # 1608, Poster # 762
Title: Cellular Aminopeptidase Inhibition as a Target for the Therapy of
AML by the Novel Agent CHR-2797
Location and timing: Poster Session I, Hall B4: Saturday, December 8,
2007, 17:30-19:30 Eastern Standard Time
Presenter: Dr Chris Jenkins (University Hospital, Cardiff, UK)
Abstract # 2505, Poster # 695
Title: Aminopeptidase Inhibition as a Targeted Treatment Strategy in
Myeloma
Location and timing: Poster Session II, Hall B4: Sunday, December 9,
2007, 18:00-20:00, Eastern Standard Time
Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)
The ASH posters will be available at the company's website, www.chromatherapeutics.com following the above presentations.
Enquiries
Chroma Therapeutics Limited
Ian Nicholson Chief Executive Officer +44 (0)1235 829120
Richard Bungay Chief Financial Officer
Brunswick
Jon Coles +44 (0)20 7404 5959
Justine McIlroy
About aminopeptidases and CHR-2797
Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.
About Chroma Therapeutics
Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.
More information about Chroma can be found at www.chromatherapeutics.com.
CONTACT: Ian Nicholson, Chief Executive Officer, or Richard Bungay, ChiefFinancial Officer, +44-0-1235-829120, both of Chroma Therapeutics Limited;or Jon Coles or Justine McIlroy, +44-0-20-7404-5959, both of Brunswick, forChroma Therapeutics Limited
Web site: http://www.chromatherapeutics.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: November 2007
